Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma

医学 易普利姆玛 无容量 内科学 福克斯 曲妥珠单抗 养生 肿瘤科 临床终点 长春瑞滨 随机对照试验 外科 胃肠病学 化疗 癌症 免疫疗法 乳腺癌 奥沙利铂 结直肠癌 顺铂
作者
Alexander Stein,Lisa Paschold,Joseph Tintelnot,Eray Goekkurt,Svenja-Sibylla Henkes,Donjetë Simnica,Christoph Schultheiß,Edith Willscher,Marcus Bauer,Claudia Wickenhauser,Peter Thuss‐Patience,Sylvie Lorenzen,Thomas J. Ettrich,Jorge Riera‐Knorrenschild,Lutz Jacobasch,Albrecht Kretzschmar,Stefan Kubicka,Salah‐Eddin Al‐Batran,Anke Reinacher‐Schick,Daniel Pink
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (8): 1150-1158 被引量:56
标识
DOI:10.1001/jamaoncol.2022.2228
摘要

Importance: In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations. Objective: To investigate the efficacy of trastuzumab and PD-1 inhibitors with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors or FOLFOX in first-line treatment of advanced ERBB2-positive EGA. Design, Setting, and Participants: This phase 2 multicenter, outpatient, randomized clinical trial with 2 experimental arms compared with historical control individually was conducted between March 2018 and May 2020 across 21 German sites. The reported results are based on a median follow-up of 14.3 months. Patients with previously untreated, metastatic ERBB2-positive (local immunohistochemistry score of 3+ or 2+/in situ hybridization amplification positive) EGA, adequate organ function, and eligibility for immunotherapy were included. Data analysis was performed from June to September 2021. Interventions: Patients were randomized to trastuzumab and nivolumab (1 mg/kg × 4/240 mg for up to 12 months) in combination with mFOLFOX6 (FOLFOX arm) or ipilimumab (3 mg/kg × 4 for up to 12 weeks) (ipilimumab arm). Main Outcomes and Measures: The primary end point was survival improvement with a targeted increase of the 12-month overall survival rate from 55% (trastuzumab/chemotherapy-ToGA regimen) to 70% in each arm. Results: A total of 97 patients were enrolled, and 88 were randomized (18 women, 70 men; median [range] age, 61 [41-80] years). Baseline Eastern Cooperative Oncology Group performance status was 0 in 54 patients (61%) and 1 in 34 patients (39%); 66 patients (75%) had EGA localized in the esophagogastric junction and 22 in the stomach (25%). Central post hoc biomarker analysis (84 patients) showed PD-1 ligand 1 (PD-L1) combined positive score of 1 or greater in 59 patients (72%) and 5 or greater in 46 patients (56%) and confirmed ERBB2 positivity in 76 patients. The observed overall survival rate at 12 months was 70% (95% CI, 54%-81%) with FOLFOX and 57% (95% CI, 41%-71%) with ipilimumab. Treatment-related grade 3 or greater adverse events (AEs) and serious AEs occurred in 29 and 15 patients in the FOLFOX arm and in 20 and 17 patients in the ipilimumab arm, respectively, with a higher incidence of autoimmune-related AEs in the ipilimumab arm and neuropathy in the FOLFOX arm. Liquid biopsy analyses showed strong correlation of early cell-free DNA increase with shorter progression-free and overall survival and emergence of truncating and epitope-loss ERBB2 resistance sequence variations with trastuzumab treatment. Conclusions and Relevance: In this randomized clinical trial, trastuzumab, nivolumab, and FOLFOX showed favorable efficacy compared with historical data and trastuzumab, nivolumab, and ipilimumab in ERBB2-positive EGA. The ipilimumab arm yielded similar OS compared with the ToGA regimen. Trial Registration: ClinicalTrials.gov Identifier: NCT03409848.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可耐的孱完成签到,获得积分10
刚刚
题西林壁完成签到,获得积分10
刚刚
沂今司完成签到 ,获得积分10
刚刚
liguanyu1078完成签到,获得积分10
刚刚
elsalili发布了新的文献求助10
刚刚
lee完成签到,获得积分10
1秒前
1秒前
苹果骑士完成签到,获得积分10
1秒前
1秒前
jindex完成签到,获得积分10
2秒前
乖拉完成签到,获得积分10
2秒前
2秒前
在九月完成签到 ,获得积分10
3秒前
酷酷怜雪完成签到 ,获得积分10
3秒前
3秒前
4秒前
吕奎完成签到,获得积分10
4秒前
爱撒娇的朋友完成签到,获得积分10
4秒前
yongziwu完成签到,获得积分0
4秒前
Amy完成签到,获得积分0
5秒前
5秒前
啦啦啦完成签到 ,获得积分10
5秒前
儒雅山兰完成签到,获得积分10
6秒前
daikai完成签到,获得积分10
6秒前
Sevi完成签到,获得积分10
6秒前
6秒前
Huangzhisong发布了新的文献求助10
7秒前
我爱坏女人完成签到,获得积分20
7秒前
潇洒的辣条完成签到,获得积分10
7秒前
Cc发布了新的文献求助10
7秒前
弹指一挥间完成签到,获得积分10
7秒前
甜屁儿完成签到 ,获得积分10
7秒前
7秒前
暖阳完成签到 ,获得积分10
7秒前
zdl完成签到,获得积分10
8秒前
8秒前
超级大肥宅完成签到,获得积分10
8秒前
一土它小木登子完成签到,获得积分10
9秒前
好嘞完成签到 ,获得积分10
9秒前
yy发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152197
求助须知:如何正确求助?哪些是违规求助? 9548933
关于积分的说明 21688809
捐赠科研通 7740419
什么是DOI,文献DOI怎么找? 3425136
关于科研通互助平台的介绍 2550342
邀请新用户注册赠送积分活动 2468584